# Study of Safety and Efficacy of C-CAR011 in B-NHL Patients

> **NCT03154775** · PHASE1 · UNKNOWN · sponsor: **Shanghai AbelZeta Ltd.** · enrollment: 15 (estimated)

## Conditions studied

- Refractory or Relapsed Non-Hodgkin Lymphoma

## Interventions

- **BIOLOGICAL:** C-CAR011

## Key facts

- **NCT ID:** NCT03154775
- **Lead sponsor:** Shanghai AbelZeta Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-05-03
- **Primary completion:** 2018-04-30
- **Final completion:** 2018-12-31
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2017-05-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03154775

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03154775, "Study of Safety and Efficacy of C-CAR011 in B-NHL Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03154775. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*